Literature DB >> 18025181

Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease.

Keith S Bahjat1, Rodney A Prell, Heather E Allen, Weiqun Liu, Edward E Lemmens, Meredith L Leong, Daniel A Portnoy, Thomas W Dubensky, Dirk G Brockstedt, Martin A Giedlin.   

Abstract

NK cells can identify and eliminate emerging tumors due to altered expression of activating and inhibitory ligands on aberrant cells, a process that is greatly enhanced following NK cell activation. As a principal site of both tumor metastases and immature NK cells, the liver represents a unique anatomic location in which activation of the innate immune system could provide substantial therapeutic benefit. We describe here the NK cell-dependent destruction of a primary hepatic tumor following infection with an attenuated intracellular bacterium derived from Listeria monocytogenes. NK cell-mediated immunity correlated with the ordered migration and maturation of NK cells within the liver. Cytolytic activity was partially dependent on NKG2D-mediated tumor cell recognition, but surprisingly was still effective in the absence of type I IFN. Significantly, NK cell-mediated destruction of a primary hepatic tumor in infected mice led to long-lived CD4- and CD8 T cell-dependent tumor-specific adaptive immunity. These findings establish that activation and differentiation of immature NK cells using complex microbial stimuli can elicit potent anti-tumor activity within the liver, promote cross-presentation of tumor-derived Ags leading to long-lived systemic anti-tumor immunity, and suggests a paradigm for clinical intervention of liver metastatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025181     DOI: 10.4049/jimmunol.179.11.7376

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

Authors:  Dung T Le; Dirk G Brockstedt; Ran Nir-Paz; Johannes Hampl; Shruti Mathur; John Nemunaitis; Daniel H Sterman; Raffit Hassan; Eric Lutz; Bentley Moyer; Martin Giedlin; Jana-Lynn Louis; Elizabeth A Sugar; Alice Pons; Andrea L Cox; Jordana Levine; Aimee Luck Murphy; Peter Illei; Thomas W Dubensky; Joseph E Eiden; Elizabeth M Jaffee; Daniel A Laheru
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

Review 2.  Clinical development of Listeria monocytogenes-based immunotherapies.

Authors:  Dung T Le; Thomas W Dubenksy; Dirk G Brockstedt
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 3.  Roles of liver innate immune cells in nonalcoholic fatty liver disease.

Authors:  Yu-Tao Zhan; Wei An
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

4.  The involvement of NK cell activation following intranasal administration of CpG DNA lipoplex in the prevention of pulmonary metastasis and peritoneal dissemination in mice.

Authors:  Shuwen Zhou; Shigeru Kawakami; Yuriko Higuchi; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Clin Exp Metastasis       Date:  2011-11-04       Impact factor: 5.150

5.  Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis.

Authors:  D M Foureau; T L Walling; V Maddukuri; W Anderson; K Culbreath; D E Kleiner; W A Ahrens; C Jacobs; P B Watkins; R J Fontana; N Chalasani; J Talwalkar; W M Lee; A Stolz; J Serrano; H L Bonkovsky
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

Review 6.  Immune cell-mediated liver injury.

Authors:  Nadia Corazza; Anastasia Badmann; Christoph Lauer
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

7.  Constitutive Activation of the PrfA regulon enhances the potency of vaccines based on live-attenuated and killed but metabolically active Listeria monocytogenes strains.

Authors:  Peter Lauer; Bill Hanson; Edward E Lemmens; Weiqun Liu; William S Luckett; Meredith L Leong; Heather E Allen; Justin Skoble; Keith S Bahjat; Nancy E Freitag; Dirk G Brockstedt; Thomas W Dubensky
Journal:  Infect Immun       Date:  2008-06-09       Impact factor: 3.441

Review 8.  Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.

Authors:  Jeff J Subleski; Robert H Wiltrout; Jonathan M Weiss
Journal:  J Autoimmun       Date:  2009-08-13       Impact factor: 7.094

9.  Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.

Authors:  Craig M Brackett; Bojidar Kojouharov; Jean Veith; Kellee F Greene; Lyudmila G Burdelya; Sandra O Gollnick; Scott I Abrams; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-01       Impact factor: 11.205

10.  Suppression of cell-mediated immunity following recognition of phagosome-confined bacteria.

Authors:  Keith S Bahjat; Nicole Meyer-Morse; Edward E Lemmens; Jessica A Shugart; Thomas W Dubensky; Dirk G Brockstedt; Daniel A Portnoy
Journal:  PLoS Pathog       Date:  2009-09-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.